中国2型糖尿病患者接受双时相门冬胰岛素30治疗后血糖控制达标的预测因素分析:A1chieve研究亚组数据

发布时间：2019-04-17 05:51

【摘要】：目的预测T2DM患者由预混人胰岛素(BHI30)转为双时相门冬胰岛素30(BIAsp30)后治疗达标的基线特征。方法纳入A1chieve研究中BHI30血糖控制效果不佳而转用BIAsp30治疗的中国患者,以治疗24周后HbA_1c是否达标(7.0%)为因变量,患者基线特征为自变量,行单因素及多因素回归分析。结果基线HbA_1c、FPG及体重是患者接受BIAsp30治疗后HbA_1c达标的预测因素。基线HbA_1c水平每增加1%,治疗后HbA_1c达标的可能性降低25%;基线FPG水平每增加1mmol/L,治疗后HbA_1c达标的可能性降低7%;基线体重每增加1kg,治疗后HbA_1c达标的可能降低2%。结论本研究提示,由BHI30转为BIAsp30治疗,患者基线HbA_1c、FPG及体重越低,血糖控制的达标率越高。
[Abstract]:Objective to predict the baseline characteristics of T2DM patients after conversion from premixed human insulin (BHI30) to biphasic aspartate insulin 30 (BIAsp30). Methods Chinese patients whose blood glucose control effect of BHI30 was not good and switched to BIAsp30 treatment were included in the A1chieve study. Whether or not HbA_1c reached the standard (7.0%) after 24 weeks of treatment was taken as dependent variable, and the baseline characteristics of the patients were independent variables. Univariate and multivariate regression analysis were performed. Results baseline HbA_1c,FPG and body weight were predictors of HbA_1c compliance after BIAsp30 treatment. For every 1% increase in baseline HbA_1c level, the possibility of HbA_1c reaching the standard decreased by 25% after treatment, and that of HbA_1c after treatment decreased by 7% for every increase in baseline FPG level of 1 mmol / L. For every 1kg gain in baseline body weight, HbA_1c may be reduced by 2% after treatment. Conclusion this study suggests that the lower the baseline HbA_1c,FPG and body weight, the higher the rate of reaching the standard of blood glucose control in patients with the conversion from BHI30 to BIAsp30.
【作者单位】：第二军医大学附属长征医院内分泌科;河北医科大学第三医院内分泌科;北京协和医院内分泌科;郑州大学第一附属医院内分泌科;浙江大学医学院附属第一医院内分泌科;中南大学湘雅三医院内分泌科;吉林大学中日联谊医院内分泌科;南昌大学第三附属医院内分泌科;陕西省人民医院内分泌科;
【分类号】：R587.1

【共引文献】